GSK rises as HIV and oncology portfolio powers 2026 growth outlook
GSK (NYSE:GSK) reported fourth-quarter results that cleared Wall Street estimates, as the British drugmaker successfully leveraged its high-growth specialty medicines to offset slowing demand for its flagship RSV vaccine, Arexvy.











